• Macro: Markets ended the day mixed yesterday with the Stoxx 600 broad index rising slightly, while the S&P 500 and the Nasdaq ended in the red, as investors de-risked ahead of jobs data out later today. Later this morning, Eurozone Q3 GDP growth is expected to remain at 0.9%, whilst in the US at 13:30, we have November Nonfarm Payrolls expected to come in at 218k and Unemployment rate expected to remain flat at 4.1%. At 15:00, the University of Michigan Sentiment index is expected to improve in December. Fed speakers today will include Bowman, Goolsbee, Hammack and Daly.
• Stock: We have updates on our recent meeting with Kerry Group’s CFO along with the financial terms of Aviva’s takeover deal of DirectLine. (Comment attached
• Debt: Core bond yields moved higher in Europe yesterday despite a weaker than forecast German Industrial Production print.

Opportunities this week:

• Despite the recent downward correction seen in GSK’s shares, we view it as a fundamentally solid healthcare business with a strong franchise, as such, we reiterate our BUY rating on the stock. (BUY PT: 1890p)
• Given the selloff in Kingspan’s shares over the last month (-10% in June) and the possibility the company’s H1 guidance may prove overly conservative, we believe it is an opportune time to highlight the stock as a buying opportunity. (BUY PT: €94.10)
• In our view, the recent pullback in Glanbia’s shares appears unwarranted, providing an attractive entry point for investors. (BUY PT €21.50)